NEOS Neos Therapeutics Inc.

1.98
+0.01  (+1%)
Previous Close 1.96
Open 1.98
Price To Book 12.34
Market Cap 98178587
Shares 49,710,677
Volume 81,149
Short Ratio
Av. Daily Volume 411,306

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced September 15, 2017.
NT-0201
Attention deficit hyperactivity disorder (ADHD)
Approved January 27, 2016.
Adzenys XR-ODT
Attention deficit hyperactivity disorder (ADHD)
Approval announced June 19, 2017.
Cotempla XR-ODT
Attention deficit hyperactivity disorder (ADHD)

Latest News

  1. Implied Volatility Surging for Neos Therapeutics (NEOS) Stock Options
  2. Edited Transcript of NEOS earnings conference call or presentation 14-Mar-19 12:30pm GMT
  3. Neos Therapeutics Inc (NEOS) Files 10-K for the Fiscal Year Ended on December 31, 2018
  4. Neos Therapeutics: 4Q Earnings Snapshot
  5. The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering
  6. Neos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results
  7. Neos Therapeutics to Host Fourth Quarter and Year-End 2018 Financial and Operating Results Conference Call on March 14th, 2019
  8. Neos Therapeutics to Present at the Cowen & Co. Annual Health Care Conference
  9. Report: Exploring Fundamental Drivers Behind Iamgold, Malibu Boats, Renren, 58, Neos Therapeutics, and Kimball Electronics — New Horizons, Emerging Trends, and Upcoming Developments
  10. Neos Therapeutics Announces Appointment of James Robinson to Board of Directors
  11. Teva Stock Rises on Patent Settlement With Neos Therapeutics
  12. Company News For Dec 27, 2018
  13. Neos, Teva settle litigation over ADHD drug
  14. Neos Therapeutics Announces Settlement with Teva on Cotempla XR-ODT® Patent Litigation
  15. Neos Therapeutics Announces Realignment of Commercial Organization
  16. Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer
  17. Detailed Research: Economic Perspectives on Genocea Biosciences, Big Lots, SemGroup, Conn's, Mimecast, and Neos Therapeutics — What Drives Growth in Today's Competitive Landscape
  18. Edited Transcript of NEOS earnings conference call or presentation 9-Nov-18 1:30pm GMT